Turn Therapeutics

"The pessimist complains about the wind; the optimist expects it to change; the realist adjusts the sails.” -William Ward I’ve accepted that #AMR is hard to fund, but my #MRSA program is far from dead. By pursuing #woundcare, #eczema, and #nailfungus, I’m gathering human data on our lead drug candidate that I’ll use for future indications in infection prevention. More AMR companies should remember that drugs like Rogaine and Viagra began as heart drugs, that Botox was initially for crossed eyes. There are countless blockbuster drugs that started in one indication only to end in others. If you have an AMR candidate, consider evaluating additional, venture-friendly indications to pursue, then gain data and revenue to fulfill your larger AMR dreams. Join me by investing in #dermatology and #woundcare...to help fight AMR.

If you’re in or near Nashville on 9/23, come to Vanderbilt University for this event! It already has ~200 people registered and I’m super honored to be an invited member of the panel. “Holobiome -- Film + Interactive discussion on humans, microbes, and the future of infectious diseases,” will feature short films (filmed at Vanderbilt) by Michael Graziano, whose previous films about #AMR have been featured on Netflix. Dr. Jeanne Marrazzo, head of the National Institute of Allergy and Infectious Diseases (NIAID), will provide the opening remarks. Flyer is below with QR code for registration (also via this link: https://lnkd.in/eP4hkcgQ).

It is with incredible honor and gratitude that I announce the first three members of Turn Therapeutics' newly established Business Advisory Board: Martin Dewhurst, Martin Bott, and Kent Kester. Their expertise from decades in executive positions at organizations such as Eli Lilly and Company, McKinsey & Company, Sanofi, and IAVI cannot be overstated. Their counsel has already helped shape our rapidly growing organization. All are both friends and guides, and I am absolutely elated they have accepted the invitation to join.

#AMR founders face difficult odds with funding. I speak of this as one, myself. When we began our expansion into #dermatology, StartEngine intrigued me because #crowdfunding enables the public to invest in a historically closed-off space (private Biotech/Pharma) for very low minimums. I enjoyed the idea of getting the public involved in Turn, but also saw how this could translate to AMR. Terrapinn was nice enough to sponsor this talk, themselves, so that AMR founders can learn how this very active community can support their work. Come listen to the discussion with StartEngine's Director of Fundraising, Harrison Bert, at World Anti-Microbial Resistance Congress on 9/6/24 at 11:20am, and take a look at Turn's campaign as an example:?https://t.ly/MCvSI

We can now confirm that our lead formula inhibits four key inflammatory cytokines (IL4, IL31, IL36a, IL36γ) that are involved in #eczema. Honored to have Emma Andrus and Dermatology Times share the news first. #immunology #dermatology #inflammation

Eczema in three sentences: 1. People with eczema have a gene defect that leads to excess staph in their skin. 2. The immune system releases proteins called cytokines to fight off the excess staph. 3. An unfortunate consequence of some of these helpful cytokines is that other ones are released that make you red, itchy, and miserable…we call that eczema. The beauty of simplifying the complex is that there’s almost always a simpler solution to follow. And VC’s, C-suite pharma execs, doctors, and everyday people have already put over $600,000 into our Reg CF to be part of bringing our simpler solution to market. #eczema #dermatology StartEngine, National Eczema Association, Dermatology Times

“The researchers concluded that the bacteria Staphylococcus aureus may be an important part of the puzzle. They hope their findings may eventually lead to treatments for a range of skin conditions.” We’re getting there!! If you want to be a part of it, click the following link: https://rb.gy/4xvwrl. It may end up being the only opportunity for the general public to invest in this fast-mover. Be sure to watch the video at the top of the campaign page, as well as read the recent piece by Emma Andrus on Turn Therapeutics in Dermatology Times. #eczema #dermatology

Please see the attached press release for powerful data regarding our moderate-severe atopic dermatitis candidate. #eczema #dermatology

Read about and listen to our CEO's personal story, as well as the origin story of Turn Therapeutics on WHYY, an NPR affiliate. Hosted by award-winning journalist, Maiken Scott.

In a podcast with Dermatology Times, our CEO Bradley Burnam discusses how physicians informed him of the potential for his technology to improve the quality of life for those with moderate to severe #eczema. #dermatology